News & Events
Academic Innovation Leader and Experienced Scientist to Join C-Path’s PKD Consortium
Sorin Fedeles, Ph.D., MBA to serve as new Executive Director TUCSON, Ariz., October 14, 2021 – Critical Path Institute (C-Path) today announced it has named Sorin Fedeles, Ph.D., MBA as Executive Director of its Polycystic Kidney Disease Outcomes Consortium (PKDOC), effective October 1, 2021. Dr. Fedeles comes to C-Path after 12-plus years as a scientist […]
C-Path Appoints Tufts’ Jonathan M. Davis as Senior Advisor in Pediatrics
TUCSON, Ariz., September 16, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jonathan M. Davis, M.D., as Senior Advisor in Pediatrics working with its International Neonatal Consortium (INC) and advising on drug and device development in infants and children, effective immediately. Davis is Vice-Chair of Pediatrics and Chief of Newborn Medicine at […]
Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program
C-Path, NORD and FDA host annual meeting, demonstration and launch of new rare disease data and analytics platform. TUCSON, Ariz. and WASHINGTON, September 15, 2021 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation. […]
C-Path and RARE-X Establish New Collaboration for Rare Disease Data Sharing
RARE-X and Critical Path Institute align on their mission and commitment for data sharing to improve rare disease research TUCSON, Ariz. and ALISO VIEJO, Calif., September 13, 2021 — Critical Path Institute (C-Path), who’s aim is to catalyze the development of new approaches that advance medical innovation and regulatory science, today announced a collaboration with […]
Stay connected with C-Path
C-Path Successes
- >>First preclinical safety biomarkers (7) qualified by the FDA, EMA and PMDA
- >>First imaging biomarker for trial enrichment qualified by the EMA
- >>FDA and EMA reach landmark decisions on C-Path’s Simulation Tool for Alzheimer’s disease
- >>C-Path’s Alzheimer’s Disease Simulator Featured in the Wall Street Journal
- >>C-Path and CDISC partnership delivers therapeutic area standards
- >>FDA and EMA issue first-of-their-kind Letters of Support for two Kidney Biomarkers
- >>EMA Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
- >>Regulatory Support For Autosomal Dominant Polycystic Kidney Disease Biomarker
- >>C-Path’s PKDOC Secures FDA Qualification for Enrichment Biomarker in ADPKD
- >>C-Path’s PKDOC Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD